{"title":"敦促为OCs提供标准化说明。","authors":"","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>FDA has developed standardized, simplified instructions for all brands of combined estrogen and progestogen oral contraceptives (OCs) to help reduce unplanned pregnancies. FDA asked manufacturers in April to incorporate these changes into patient package inserts as soon as possible. Since current instructions vary significantly from brand to brand, problems can occur when women switch brands and compare instructions. If they become confused, women may either take the pills incorrectly or stop altogether, risking an unwanted pregnancy. In addition to reducing patients' confusion about correct use, the new recommended instructions reflect current research on the effective use of OCs. An important change concerns when women should start taking pills. The new instructions provide only 2 options (current instructions provide more): either start on day 1 of the next normal menstrual cycle (\"Day 1 Start\") or on the 1st Sunday after the next cycle begins (\"Sunday Start\"). Although the \"Sunday Start\" option is popular, the \"Day 1 Start\" has been shown to be more effective since back-up contraceptive methods are not required for the 1st week, as they are for the \"Sunday Start.\" Other changes in the patient package insert simplify and clarify the instructions when different numbers of pills are missed. Any patient who is unsure about what to do when pills are missed is told to use a back-up method of birth control and to keep taking pills with hormones until she van consult with a health professional. The new labeling also advises women to consult a health professional regarding other methods of contraception if taking a daily pill is a problem. These new directions for patients are for combination pills and do not apply to progestin-only OCs. FDA is still developing new labeling for them. FDA's Fertility and Maternal Health Advisory Committee recommended on FEb. 8, 1991, that the agency ask manufacturers of OCs to make these changes in the patient package insert.</p>","PeriodicalId":84736,"journal":{"name":"FDA medical bulletin : important information for health professionals from the U.S. Food & Drug Administration","volume":"22 2","pages":"6-7"},"PeriodicalIF":0.0000,"publicationDate":"1992-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Standardized instructions urged for OCs.\",\"authors\":\"\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>FDA has developed standardized, simplified instructions for all brands of combined estrogen and progestogen oral contraceptives (OCs) to help reduce unplanned pregnancies. FDA asked manufacturers in April to incorporate these changes into patient package inserts as soon as possible. Since current instructions vary significantly from brand to brand, problems can occur when women switch brands and compare instructions. If they become confused, women may either take the pills incorrectly or stop altogether, risking an unwanted pregnancy. In addition to reducing patients' confusion about correct use, the new recommended instructions reflect current research on the effective use of OCs. An important change concerns when women should start taking pills. The new instructions provide only 2 options (current instructions provide more): either start on day 1 of the next normal menstrual cycle (\\\"Day 1 Start\\\") or on the 1st Sunday after the next cycle begins (\\\"Sunday Start\\\"). Although the \\\"Sunday Start\\\" option is popular, the \\\"Day 1 Start\\\" has been shown to be more effective since back-up contraceptive methods are not required for the 1st week, as they are for the \\\"Sunday Start.\\\" Other changes in the patient package insert simplify and clarify the instructions when different numbers of pills are missed. Any patient who is unsure about what to do when pills are missed is told to use a back-up method of birth control and to keep taking pills with hormones until she van consult with a health professional. The new labeling also advises women to consult a health professional regarding other methods of contraception if taking a daily pill is a problem. These new directions for patients are for combination pills and do not apply to progestin-only OCs. FDA is still developing new labeling for them. FDA's Fertility and Maternal Health Advisory Committee recommended on FEb. 8, 1991, that the agency ask manufacturers of OCs to make these changes in the patient package insert.</p>\",\"PeriodicalId\":84736,\"journal\":{\"name\":\"FDA medical bulletin : important information for health professionals from the U.S. Food & Drug Administration\",\"volume\":\"22 2\",\"pages\":\"6-7\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1992-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"FDA medical bulletin : important information for health professionals from the U.S. Food & Drug Administration\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"FDA medical bulletin : important information for health professionals from the U.S. Food & Drug Administration","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

FDA已经为所有品牌的雌激素和孕激素联合口服避孕药(OCs)制定了标准化、简化的说明,以帮助减少意外怀孕。FDA在4月份要求制造商尽快将这些变化纳入患者包装说明书。由于目前不同品牌的说明书差异很大,当女性更换品牌并比较说明书时,就会出现问题。如果他们感到困惑,女性可能会错误地服用药物或完全停止服用,从而冒着意外怀孕的风险。除了减少患者对正确使用的困惑外,新的推荐指南反映了目前对OCs有效使用的研究。一个重要的变化是女性何时应该开始服用避孕药。新说明书只提供两种选择(现有说明书提供更多):在下一个正常月经周期的第一天开始(“第一天开始”)或在下一个月经周期开始后的第一个星期日开始(“星期日开始”)。虽然“周日开始”选项很受欢迎,但“第一天开始”已被证明更有效,因为第一周不需要备用避孕方法,因为它们是“周日开始”。在患者包装说明书的其他变化简化和澄清说明时,不同数量的药丸遗漏。如果病人不确定错过避孕药后该怎么做,医生会告诉她使用备用避孕方法,并继续服用含有激素的避孕药,直到咨询健康专家。新的标签还建议女性如果每天服用避孕药有问题,请咨询健康专家,了解其他避孕方法。这些针对患者的新指示是联合用药,不适用于仅使用黄体酮的OCs。FDA仍在为它们制定新的标签。1991年2月8日,FDA生育和孕产妇健康咨询委员会建议,该机构要求OCs制造商在患者包装说明书中做出这些改变。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Standardized instructions urged for OCs.

FDA has developed standardized, simplified instructions for all brands of combined estrogen and progestogen oral contraceptives (OCs) to help reduce unplanned pregnancies. FDA asked manufacturers in April to incorporate these changes into patient package inserts as soon as possible. Since current instructions vary significantly from brand to brand, problems can occur when women switch brands and compare instructions. If they become confused, women may either take the pills incorrectly or stop altogether, risking an unwanted pregnancy. In addition to reducing patients' confusion about correct use, the new recommended instructions reflect current research on the effective use of OCs. An important change concerns when women should start taking pills. The new instructions provide only 2 options (current instructions provide more): either start on day 1 of the next normal menstrual cycle ("Day 1 Start") or on the 1st Sunday after the next cycle begins ("Sunday Start"). Although the "Sunday Start" option is popular, the "Day 1 Start" has been shown to be more effective since back-up contraceptive methods are not required for the 1st week, as they are for the "Sunday Start." Other changes in the patient package insert simplify and clarify the instructions when different numbers of pills are missed. Any patient who is unsure about what to do when pills are missed is told to use a back-up method of birth control and to keep taking pills with hormones until she van consult with a health professional. The new labeling also advises women to consult a health professional regarding other methods of contraception if taking a daily pill is a problem. These new directions for patients are for combination pills and do not apply to progestin-only OCs. FDA is still developing new labeling for them. FDA's Fertility and Maternal Health Advisory Committee recommended on FEb. 8, 1991, that the agency ask manufacturers of OCs to make these changes in the patient package insert.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
"Female condom" approved. New labeling to provide information about contraceptives and STDs. 3-month contraceptive injection approved. Standardized instructions urged for OCs.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1